Breast Cancer | Specialty

Dr. Hope Rugo on Trastuzumab Biosimilar in HER2-Positive Breast Cancer

August 24th 2016

EMA Initiates Official Regulatory Review of Neratinib in HER2+ Breast Cancer

August 23rd 2016

The European Medicines Agency has validated the marketing authorization application for neratinib as a potential extended adjuvant therapy for patients with HER2-positive early stage breast cancer following 12 months of trastuzumab.

Dr. Hudis on Combating Obesity in Breast Cancer

August 18th 2016

Clifford A. Hudis, MD, CEO, ASCO, discusses how oncologists should be helping patients with breast cancer overcome obesity.

Dr. Joyce O'Shaughnessy on Promising Agents in Triple-Negative Breast Cancer

August 17th 2016

Joyce O'Shaughnessy, MD, co-chair, breast cancer research, chair breast cancer at Baylor-Sammons Cancer Center, discusses what’s on the horizon in triple-negative breast cancer (TNBC). Checkpoint inhibitors, such as an anti-PD-1 agents, show a lot of promise in TNBC, said O’Shaughnessy. There are several studies investigating the use of checkpoint inhibitors with platinum agents and the preliminary data looks very good, she said.

Dr. Hurvitz on Steps to Take With HER2-Positive Breast Cancer Research

August 17th 2016

Sara Hurvitz, MD, medical oncologist, General Internal Medicine, Hematology and Oncology at UCLA, discusses steps needed to take in the field of HER2-positive breast cancer from a research perspective.

ASCO Recommends Standard Lumpectomy Margin Width for DCIS

August 15th 2016

A 2-mm margin should be the standard for patients with ductal carcinoma in situ undergoing breast conserving surgery with whole breast irradiation.

Early Abemaciclib Data Not Sufficient to Halt Phase III Breast Cancer Trial

August 10th 2016

The phase III MONARCH 2 study assessing abemaciclib in HR-positive, HER2-negative advanced breast cancer will continue after the CDK4/6 inhibitor did not meet the efficacy criteria at an interim analysis required to stop the trial early.

Dr. Dixon on Prevalence and Risk Factors of Male Breast Cancer

August 10th 2016

J. Michael Dixon, MD, professor of Surgery, consultant surgeon, and clinical director of the Breakthrough Breast Cancer Research Unit at the University of Edinburgh in Scotland, discusses the prevalence of and risk factors for breast cancer in males.

Dr. Frankie Ann Holmes on Duel Anti-HER2-Directed Therapy in Breast Cancer

August 10th 2016

Dr. Arteaga on Ongoing Trials in Metastatic Breast Cancer

August 9th 2016

Carlos L. Arteaga, MD, associate director for Clinical Research, director, Center for Cancer Targeted Therapies, Vanderbilt-Ingram Cancer Center, discusses some of the ongoing trials exploring treatments for patients with metastatic breast cancer.

Dr. Lehman on 3D Mammography in Screening for Breast Cancer

August 8th 2016

Constance D. Lehman, MD, PhD, professor of radiology and chief of Breast Imaging in the Department of Radiology at Massachusetts General Hospital, discusses how 3D mammography has been an efficient and beneficial screening tool in the field of breast cancer.

Dr. Harold J. Burstein on CDK4/CDK6 Inhibitor Abemaciclib in Breast Cancer

August 7th 2016

​Harold J. Burstein, MD, PhD, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute discusses the results of MONARCH1, which looked at abemaciclib as monotherapy in patients with ER-positive breast cancer, after chemotherapy for advanced disease.

Dr. Kuerer on De-Escalating Surgery in the Treatment of Patients With Breast Cancer

August 5th 2016

Henry M. Kuerer, MD, PhD, professor of Surgery, PH and Fay Etta Robinson Distinguished Professor in Research, Breast Surgical Oncology, executive director, Breast Programs, director, Breast Surgical Oncology Fellowship Training Program, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses de-escalating surgery in the treatment of patients with breast cancer.

FDA Grants Ribociclib Breakthrough Designation for Breast Cancer

August 3rd 2016

The FDA has granted a breakthrough therapy designation to the CDK4/6 inhibitor ribociclib in combination with letrozole for its potential as a frontline therapy for patients with HR-positive, HER2-negative advanced breast cancer.

Dr. Yardley on Unmet Need for Patients With HER2+ Breast Cancer

August 3rd 2016

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the unmet need for patients with HER2-positive breast cancer.

Dr. Holmes Discusses Late Recurrence and the MA.17R Trial in Breast Cancer

July 30th 2016

Dr. Bellon on Ongoing Trials in Omitting Radiation in Breast Cancer Treatment

July 29th 2016

Jennifer Bellon, MD, radiation oncologist, Dana-Farber Cancer Institute, discusses some of the current ongoing trials looking at omitting radiation when it comes to the treatment of patients with breast cancer.

Study Supports Use of Anthracyclines for Early, HER2-Negative Breast Cancer

July 29th 2016

Treatment with anthracyclines was proven to be beneficial for patients with high-risk, HER2-negative, early-stage breast cancer, according to a joint analysis of the Anthracyclines in Early Breast Cancer (ABC) trials.

Dr. Ma on the METRIC Trial in Triple-Negative Breast Cancer

July 28th 2016

Cynthia Ma, MD, PhD, associate professor of Medicine, Washington University School of Medicine, discusses the METRIC trial in triple-negative breast cancer.

Immunotherapy, Targeted Options Emerge in Triple-Negative Breast Cancer

July 28th 2016

Cynthia Ma, MD, provides insight on the potential of glembatumumab vedotin (CDX-011) and immunotherapies on the horizon in the field of triple-negative breast cancer.